Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.
Company profile
Ticker
CORBF
Exchange
Website
CEO
Ting Zheng
Employees
Location
Fiscal year end
Industry (SIC)
Former names
China Cord Blood Corp
SEC CIK
CORBF stock data
Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
19 Mar 24
6-K
Report of Foreign Private Issuer
11 Mar 24
6-K
Report of Foreign Private Issuer
12 Feb 24
6-K
Report of Foreign Private Issuer
4 Dec 23
6-K
In the Grand Court of the Cayman Islands Financial Services Division
29 Sep 23
6-K
Report of Foreign Private Issuer
5 Sep 23
NT 20-F
Notice of late annual filing (foreign)
11 Aug 23
25-NSE
Exchange delisting
22 Jun 23
6-K
Report of Foreign Private Issuer
2 Jun 23
6-K
Report of Foreign Private Issuer
10 Apr 23
Latest ownership filings
SC 13G/A
Oasis Management Co Ltd.
11 Mar 24
SC 13G/A
Oasis Management Co Ltd.
14 Feb 24
SC 13G
Oasis Management Co Ltd.
14 Feb 23
SC 13G/A
JAYHAWK CAPITAL MANAGEMENT, L.L.C.
3 Feb 23
SC 13G
Pacific Alliance Group Ltd
3 Feb 23
SC 13D/A
Blue Ocean Structure Investment Co Ltd
23 Sep 22
SC 13D/A
Blue Ocean Structure Investment Co Ltd
24 Aug 22
SC 13D/A
Blue Ocean Structure Investment Co Ltd
22 Jun 22
SC 13D/A
Blue Ocean Structure Investment Co Ltd
16 Jun 22
SC 13D/A
Blue Ocean Structure Investment Co Ltd
15 Jun 22
Financial summary
Quarter (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
82.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 2 |
Closed positions | 20 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 284.62 mm |
Total shares | 100.76 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Golden Meditech Stem Cells | 78.87 mm | $194.03 mm |
Pacific Alliance | 9.50 mm | $0.00 |
Magnum Opus International | 6.61 mm | $26.10 mm |
Jayhawk Capital Management, L.L.C. | 5.72 mm | $0.00 |
Rhumbline Advisers | 44.76 k | $46.99 mm |
Marshall Wace | 12.33 k | $12.95 mm |
Umb Bank N A | 3.98 k | $4.18 mm |
Operose Advisors | 200.00 | $210.00 k |
Steward Partners Investment Advisory | 150.00 | $158.00 k |